CA2910206C - Nouvelle composition therapeutique - Google Patents

Nouvelle composition therapeutique Download PDF

Info

Publication number
CA2910206C
CA2910206C CA2910206A CA2910206A CA2910206C CA 2910206 C CA2910206 C CA 2910206C CA 2910206 A CA2910206 A CA 2910206A CA 2910206 A CA2910206 A CA 2910206A CA 2910206 C CA2910206 C CA 2910206C
Authority
CA
Canada
Prior art keywords
jwh
composition
cannabinoid
tetrahydrocannabinol
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2910206A
Other languages
English (en)
Other versions
CA2910206A1 (fr
Inventor
Pankaj Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ctt Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2910206A priority Critical patent/CA2910206C/fr
Publication of CA2910206A1 publication Critical patent/CA2910206A1/fr
Application granted granted Critical
Publication of CA2910206C publication Critical patent/CA2910206C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

On propose une composition qui comprend un composé de tétrahydrocannabinoïde, un second cannabinoïde et un corticostéroïde. La composition est utile dans le traitement du psoriasis et des affections connexes chez un mammifère.
CA2910206A 2015-10-23 2015-10-23 Nouvelle composition therapeutique Active CA2910206C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2910206A CA2910206C (fr) 2015-10-23 2015-10-23 Nouvelle composition therapeutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2910206A CA2910206C (fr) 2015-10-23 2015-10-23 Nouvelle composition therapeutique

Publications (2)

Publication Number Publication Date
CA2910206A1 CA2910206A1 (fr) 2015-12-28
CA2910206C true CA2910206C (fr) 2016-12-13

Family

ID=54978851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2910206A Active CA2910206C (fr) 2015-10-23 2015-10-23 Nouvelle composition therapeutique

Country Status (1)

Country Link
CA (1) CA2910206C (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
AU2017387141A1 (en) * 2016-12-29 2019-07-18 Pure Ratios Holdings, Inc. Modular transdermal delivery system and associated methods of manufacture and use
CA3089994A1 (fr) 2018-01-31 2019-08-08 Canopy Holdings, LLC Poudre de chanvre
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
WO2020077153A1 (fr) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthèse du cannabigérol
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US11602504B2 (en) 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US20210322306A1 (en) * 2020-04-21 2021-10-21 Cure Pharmaceutical Holding Corp. Oral dissolvable film with high load of polymeric binder

Also Published As

Publication number Publication date
CA2910206A1 (fr) 2015-12-28

Similar Documents

Publication Publication Date Title
US9833461B2 (en) Therapeutic compositions comprising cannabidiol and corticosteroids
CA2910206C (fr) Nouvelle composition therapeutique
CA2646667C (fr) Methode de traitement des bouffees de chaleur par des preparations transdermiquea ou transmucosiques
DK1562531T3 (en) TOPICAL SKIN CARE COMPOSITION
CN104812398B (zh) 局部组合物及其使用方法
JP4549006B2 (ja) ゲル軟膏
US9775789B2 (en) Topical liposome compositions containing phenolic anti-inflammatory agents and their methods of preparation
US20190255014A1 (en) Therapeutic Cannabinoid Formulations and Methods for Their Use
US20140057881A1 (en) Composition for the Treatment of Skin Conditions
TR201819658T4 (tr) Akne Lezyonlarını Tedavi Etmek İçin Adapalen Ve Benzoil Peroksit Kombinasyonu
JP5052558B2 (ja) ゲル軟膏
KR20130020742A (ko) 모낭 표적 조성물
JP2016130224A (ja) 外用組成物
CN102048724A (zh) 用于治疗皮肤的过氧化苯甲酰组合物
CN115151241A (zh) Cbd制剂及其用途
AU2008203101A1 (en) Topical compositions comprising telmesteine for treating dermatological disorders
US20210369667A1 (en) Compositions and methods for the prevention and treatment of radiation dermatitis, eczema, burns, wounds and certain cancers
US20100068284A1 (en) Stable Fixed Dose Topical Formulation
EP3411014B1 (fr) Nouvelles compositions topiques comprenant de l'acide usnique et leur utilisation thérapeutique
WO2023168004A1 (fr) Formulation topique destinée à diminuer l'inflammation ou la rougeur de la peau
US9173940B1 (en) Mixture of betamethasone and tranilast with a transdermal gel for scar treatment
CA3040867C (fr) Compositions halobetasol propionate
JP7751966B2 (ja) 外用組成物
US20170119792A1 (en) Methods and compositions for dermatological use comprising clobetasol and halobetasol and biopolymers
WO2011113826A1 (fr) Nouvelle formulation de corticostéroïde topique

Legal Events

Date Code Title Description
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250423